z-logo
open-access-imgOpen Access
Prospective Study of Antibiotic Prophylaxis for Prostate Biopsy Involving >1100 Men
Author(s) -
Rustom P. Manecksha,
Gregory J. Nason,
Ivor M. Cullen,
Jérôme Fennell,
Elizabeth McEvoy,
Ted McDermott,
Robert J. Flynn,
Ronald G. Grainger,
John Thornhill
Publication year - 2012
Publication title -
the scientific world journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.453
H-Index - 93
eISSN - 2356-6140
pISSN - 1537-744X
DOI - 10.1100/2012/650858
Subject(s) - meropenem , regimen , ofloxacin , medicine , prostate biopsy , quinolone , antibiotics , incidence (geometry) , moxifloxacin , surgery , sepsis , urology , gastroenterology , antibiotic resistance , prostate , ciprofloxacin , microbiology and biotechnology , biology , physics , optics , cancer
We aimed to compare infection rates for two 3-day antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy (TRUSgbp) and demonstrate local microbiological trends. In 2008, 558 men and, in 2009, 625 men had TRUSgpb. Regimen 1 (2008) comprised 400 mg Ofloxacin immediately before biopsy and 200 mg 12-hourly for 3 days. Regimen 2 (2009) comprised Ofloxacin 200 mg 12-hourly for 3 days commencing 24 hours before biopsy. 20/558 (3.6%) men had febrile episodes with regimen 1 and 10/625 (1.6%) men with regimen 2 ( P = 0.03). E. coli was the most frequently isolated organism. Overall, 7/13 (54%) of positive urine cultures were quinolone resistant and (5/13) 40% were multidrug resistant. Overall, 5/9 (56%) patients with septicaemia were quinolone resistant. All patients were sensitive to Meropenem. There was 1 (0.2%) death with regimen 1. Commencing Ofloxacin 24 hours before TRUSgpb reduced the incidence of febrile episodes significantly. We observed the emergence of quinolone and multidrug-resistant E. coli . Meropenem should be considered for unresolving sepsis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom